GPT and liver disorder: According to international guidelines, AVT is indicated in the immune-active (IA) phase in patients with HBeAg-positive CHB.5–8 In contrast, the immune-tolerant (IT) phase, which is characterized by a high serum HBV-DNA level and normal alanine aminotransferase (ALT) level, is not indicative of AVT, because it is known that the IT phase has a minimal liver injury in histology and thus has a negligible risk of liver disease progression.9,10